February 2010 Volume 28 Number 2, pp 103 - 180
Visit Nature Biotechnology online to browse the journal.
Now available at http://links.ealert.nature.com/ctt?kn=24&m=34609148&r=MTc3MTg2NzE2NgS2&b=2&j=NjY5MjEzNjgS1&mt=1&rt=0
Please note that you need to be a subscriber to enjoy full text access to Nature Biotechnology online. To purchase a subscription, please visit:
http://links.ealert.nature.com/ctt?kn=105&m=34609148&r=MTc3MTg2NzE2NgS2&b=2&j=NjY5MjEzNjgS1&mt=1&rt=0
Alternatively, to recommend a subscription to your library, please visit
http://links.ealert.nature.com/ctt?kn=160&m=34609148&r=MTc3MTg2NzE2NgS2&b=2&j=NjY5MjEzNjgS1&mt=1&rt=0
Bioentrepreneur: an online resource for budding business in the life sciences.
http://links.ealert.nature.com/ctt?kn=89&m=34609148&r=MTc3MTg2NzE2NgS2&b=2&j=NjY5MjEzNjgS1&mt=1&rt=0
=========================== ADVERTISEMENT ===========================
In a field of choices Thermo Scientific SuperChip AdvaNCe stands out.
> Proven uniformity and consistency
> Excellent signal : noise ratios
> Standard and custom formats
> Isn't it obvious?
Get your free sample today.
Thermo Scientific SuperChip AdvaNCe,
Nitrocellulose-coated microarray substrates
=====================================================================
=========================== ADVERTISEMENT ===========================
Solaris qPCR Gene Expression Assays
Take the guesswork out of selecting a qPCR assay. With one search of your gene, receive one recommended, pre-designed probe and primer assay for optimal real-time PCR quantification. Introducing Thermo Scientific Solaris qPCR Gene Expression Assays- designed to perform under universal thermal cycling conditions and to detect all known splice variants of your target gene.
=====================================================================
=========================== ADVERTISEMENT ===========================
BIOPARTNERING
Visit our Biopartnering site to view Company Profiles and Partnership Opportunities:
=====================================================================
=========================== ADVERTISEMENT ===========================
nature.com Open Innovation Pavilion
Solve for a cause!
Nature Publishing Group is proud to sponsor a Challenge by the Drugs for Neglected Diseases initiative. Your ideas to solve this Challenge can help change the lives of those suffering from African sleeping sickness, Chagas disease or Leishmaniasis.
Visit http://links.ealert.nature.com/ctt?kn=112&m=34609148&r=MTc3MTg2NzE2NgS2&b=2&j=NjY5MjEzNjgS1&mt=1&rt=0 to read more about this Challenge and how you can help.
=====================================================================
----------------------
EDITORIALS
----------------------
PhRMA wants you! p103
doi:10.1038/nbt0210-103a
The biotech brand is in danger of being sullied by the blurring of pharma and biotech boundaries.
http://links.ealert.nature.com/ctt?kn=81&m=34609148&r=MTc3MTg2NzE2NgS2&b=2&j=NjY5MjEzNjgS1&mt=1&rt=0
Impossible fixes p103
doi:10.1038/nbt0210-103b
Impractical solutions to European biotech financing don't help anyone.
http://links.ealert.nature.com/ctt?kn=16&m=34609148&r=MTc3MTg2NzE2NgS2&b=2&j=NjY5MjEzNjgS1&mt=1&rt=0
----------------------
NEWS
----------------------
PML problems loom for Rituxan pp105 - 106
Malorye Allison
doi:10.1038/nbt0210-105
http://links.ealert.nature.com/ctt?kn=19&m=34609148&r=MTc3MTg2NzE2NgS2&b=2&j=NjY5MjEzNjgS1&mt=1&rt=0
Pfizer stakes a claim in plant cell-made biopharmaceuticals pp107 - 108
Mark Ratner
doi:10.1038/nbt0210-107
http://links.ealert.nature.com/ctt?kn=8&m=34609148&r=MTc3MTg2NzE2NgS2&b=2&j=NjY5MjEzNjgS1&mt=1&rt=0
Amylin's $1 billion heavyweight deal p109
Hayley Birch
doi:10.1038/nbt0210-109
http://links.ealert.nature.com/ctt?kn=12&m=34609148&r=MTc3MTg2NzE2NgS2&b=2&j=NjY5MjEzNjgS1&mt=1&rt=0
Peruvian GM advocate faces criminal charges p110
Lucas Laursen
doi:10.1038/nbt0210-110a
http://links.ealert.nature.com/ctt?kn=92&m=34609148&r=MTc3MTg2NzE2NgS2&b=2&j=NjY5MjEzNjgS1&mt=1&rt=0
EC convenes crisis talks on European biotech sector pp110 - 111
Dan Jones
doi:10.1038/nbt0210-110b
http://links.ealert.nature.com/ctt?kn=94&m=34609148&r=MTc3MTg2NzE2NgS2&b=2&j=NjY5MjEzNjgS1&mt=1&rt=0
Irish bioethics council axed p112
Cormac Sheridan
doi:10.1038/nbt0210-112a
http://links.ealert.nature.com/ctt?kn=120&m=34609148&r=MTc3MTg2NzE2NgS2&b=2&j=NjY5MjEzNjgS1&mt=1&rt=0
Amgen trumps Roche p112
Nazlie Latefi
doi:10.1038/nbt0210-112b
http://links.ealert.nature.com/ctt?kn=118&m=34609148&r=MTc3MTg2NzE2NgS2&b=2&j=NjY5MjEzNjgS1&mt=1&rt=0
Report blames GM crops for herbicide spike, downplays pesticide reductions pp112 - 113
Cormac Sheridan
doi:10.1038/nbt0210-112c
http://links.ealert.nature.com/ctt?kn=123&m=34609148&r=MTc3MTg2NzE2NgS2&b=2&j=NjY5MjEzNjgS1&mt=1&rt=0
Industry gains on moneyback schemes p114
Asher Mullard
doi:10.1038/nbt0210-114a
http://links.ealert.nature.com/ctt?kn=110&m=34609148&r=MTc3MTg2NzE2NgS2&b=2&j=NjY5MjEzNjgS1&mt=1&rt=0
$2 million rice verdict against Bayer p114
Jeffrey L Fox
doi:10.1038/nbt0210-114b
http://links.ealert.nature.com/ctt?kn=116&m=34609148&r=MTc3MTg2NzE2NgS2&b=2&j=NjY5MjEzNjgS1&mt=1&rt=0
Biorefineries' stimulus win pp114 - 115
Emily Waltz
doi:10.1038/nbt0210-114c
http://links.ealert.nature.com/ctt?kn=114&m=34609148&r=MTc3MTg2NzE2NgS2&b=2&j=NjY5MjEzNjgS1&mt=1&rt=0
Purpose-built chromosome p115
doi:10.1038/nbt0210-115a
http://links.ealert.nature.com/ctt?kn=62&m=34609148&r=MTc3MTg2NzE2NgS2&b=2&j=NjY5MjEzNjgS1&mt=1&rt=0
FDA balks on MedImmune's cell-grown flu vaccine p115
Wendy Wolfson
doi:10.1038/nbt0210-115b
http://links.ealert.nature.com/ctt?kn=66&m=34609148&r=MTc3MTg2NzE2NgS2&b=2&j=NjY5MjEzNjgS1&mt=1&rt=0
DATA PAGE
2009: Turning the corner p116
Walter Yang
doi:10.1038/nbt0210-116
http://links.ealert.nature.com/ctt?kn=52&m=34609148&r=MTc3MTg2NzE2NgS2&b=2&j=NjY5MjEzNjgS1&mt=1&rt=0
NEWS FEATURE
The HER2 testing conundrum pp117 - 119
Malorye Allison
doi:10.1038/nbt0210-117
Problems in interpreting diagnostic tests for HER2 may be compromising patient access to effective treatments. As new versions of therapies targeting HER2 work their way through clinical trials, will the situation get even murkier? Malorye Allison investigates.
http://links.ealert.nature.com/ctt?kn=47&m=34609148&r=MTc3MTg2NzE2NgS2&b=2&j=NjY5MjEzNjgS1&mt=1&rt=0
=========================== ADVERTISEMENT ===========================
Essential resource for top-level data and analysis covering the Biotechnology industry. Spot future trends and developments with this report.
Click here now:
=====================================================================
----------------------
BIOENTREPRENEUR
----------------------
BUILDING A BUSINESS
Coming to terms
David H Oden, Jeffrey A Wolfson and Christina W Marshall
doi:10.1038/bioe.2009.12
Before taking other people's money to finance your venture, it pays to fully educate yourself about the strings attached.
http://links.ealert.nature.com/ctt?kn=51&m=34609148&r=MTc3MTg2NzE2NgS2&b=2&j=NjY5MjEzNjgS1&mt=1&rt=0
----------------------
OPINION AND COMMENT
----------------------
CORRESPONDENCE
Fab-arm exchange pp123 - 125
Ellen Broug, Philip A Bland-Ward, John Powell and Kevin S Johnson
doi:10.1038/nbt0210-123
http://links.ealert.nature.com/ctt?kn=50&m=34609148&r=MTc3MTg2NzE2NgS2&b=2&j=NjY5MjEzNjgS1&mt=1&rt=0
Reply to Fab-arm exchange pp125 - 126
Aran F Labrijn, Janine Schuurman, Jan G J van de Winkel and Paul W H I Parren
doi:10.1038/nbt0210-125
http://links.ealert.nature.com/ctt?kn=84&m=34609148&r=MTc3MTg2NzE2NgS2&b=2&j=NjY5MjEzNjgS1&mt=1&rt=0
An economic and technical evaluation of microalgal biofuels pp126 - 128
Evan Stephens et al.
doi:10.1038/nbt0210-126
http://links.ealert.nature.com/ctt?kn=82&m=34609148&r=MTc3MTg2NzE2NgS2&b=2&j=NjY5MjEzNjgS1&mt=1&rt=0
Ontology engineering pp128 - 130
Gil Alterovitz et al.
doi:10.1038/nbt0210-128
http://links.ealert.nature.com/ctt?kn=74&m=34609148&r=MTc3MTg2NzE2NgS2&b=2&j=NjY5MjEzNjgS1&mt=1&rt=0
COMMENTARY
Never again p131
Christopher Scott
doi:10.1038/nbt0210-131
In 2008, Roche acquired Genentech, ending the most successful symbiotic business relationship the biotech/pharma sector has ever seen. Morphing biotech business models, pharma management's short-termism and dwindling investor patience means we'll never see the like of it again.
http://links.ealert.nature.com/ctt?kn=72&m=34609148&r=MTc3MTg2NzE2NgS2&b=2&j=NjY5MjEzNjgS1&mt=1&rt=0
Going to ridiculous lengths - European coexistence regulations for GM crops pp133 - 136
Koreen Ramessar, Teresa Capell, Richard M Twyman and Paul Christou
doi:10.1038/nbt0210-133
Even if a GM crop can surmount Europe's excessive product registration process, any farmer hoping to plant it must then navigate tortuous, arbitrary and scientifically unjustifiable coexistence regulations.
http://links.ealert.nature.com/ctt?kn=69&m=34609148&r=MTc3MTg2NzE2NgS2&b=2&j=NjY5MjEzNjgS1&mt=1&rt=0
----------------------
FEATURES
----------------------
PATENTS
Changing the rules of the game: addressing the conflict between free access to scientific discovery and intellectual property rights pp137 - 140
Miriam Bentwich
doi:10.1038/nbt0210-137
A provisional patented paper application procedure could promote earlier disclosure of novel scientific knowledge.
http://links.ealert.nature.com/ctt?kn=28&m=34609148&r=MTc3MTg2NzE2NgS2&b=2&j=NjY5MjEzNjgS1&mt=1&rt=0
Recent patent applications in antibody fragments p141
doi:10.1038/nbt0210-141
http://links.ealert.nature.com/ctt?kn=29&m=34609148&r=MTc3MTg2NzE2NgS2&b=2&j=NjY5MjEzNjgS1&mt=1&rt=0
----------------------
NEWS AND VIEWS
----------------------
ChIPs and regulatory bits pp142 - 143
Xin He and Saurabh Sinha
doi:10.1038/nbt0210-142
Machine learning reveals combinatorial patterns of transcription factor binding that drive gene expression.
http://links.ealert.nature.com/ctt?kn=3&m=34609148&r=MTc3MTg2NzE2NgS2&b=2&j=NjY5MjEzNjgS1&mt=1&rt=0
From genomics to crop breeding pp144 - 145
Richard Flavell
doi:10.1038/nbt0210-144
New insights into the maize genome must be incorporated into breeding programs to realize the potential of crop genomics.
http://links.ealert.nature.com/ctt?kn=5&m=34609148&r=MTc3MTg2NzE2NgS2&b=2&j=NjY5MjEzNjgS1&mt=1&rt=0
Spilling the beans on legume biology p145
Peter Hare
doi:10.1038/nbt0210-145
http://links.ealert.nature.com/ctt?kn=9&m=34609148&r=MTc3MTg2NzE2NgS2&b=2&j=NjY5MjEzNjgS1&mt=1&rt=0
Systematic tracking of cell fate changes pp146 - 147
Jonghwan Kim and Stuart H Orkin
doi:10.1038/nbt0210-146
High-throughput measurements across several regulatory levels provide a comprehensive view of ES-cell differentiation.
http://links.ealert.nature.com/ctt?kn=13&m=34609148&r=MTc3MTg2NzE2NgS2&b=2&j=NjY5MjEzNjgS1&mt=1&rt=0
----------------------
RESEARCH HIGHLIGHTS
----------------------
Research highlights p148
Kathy Aschheim, Laura DeFrancesco, Markus Elsner and Craig Mak
doi:10.1038/nbt0210-148
http://links.ealert.nature.com/ctt?kn=44&m=34609148&r=MTc3MTg2NzE2NgS2&b=2&j=NjY5MjEzNjgS1&mt=1&rt=0
----------------------
COMPUTATIONAL BIOLOGY
----------------------
RESOURCE
Rational association of genes with traits using a genome-scale gene network for Arabidopsis thaliana pp149 - 156
Insuk Lee et al.
doi:10.1038/nbt.1603
Abstract: http://links.ealert.nature.com/ctt?kn=96&m=34609148&r=MTc3MTg2NzE2NgS2&b=2&j=NjY5MjEzNjgS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=34&m=34609148&r=MTc3MTg2NzE2NgS2&b=2&j=NjY5MjEzNjgS1&mt=1&rt=0
----------------------
RESEARCH
----------------------
BRIEF COMMUNICATION
Enhanced antibody half-life improves in vivo activity pp157 - 159
Jonathan Zalevsky et al.
doi:10.1038/nbt.1601
A correlation between drug exposure and efficacy has never been demonstrated for therapeutic antibodies. Zalevsky et al. use a humanized mouse model to show that a reduction in antibody clearance engineered through increased antibody affinity for the neonatal Fc receptor enhances antitumor activity.
Abstract: http://links.ealert.nature.com/ctt?kn=95&m=34609148&r=MTc3MTg2NzE2NgS2&b=2&j=NjY5MjEzNjgS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=38&m=34609148&r=MTc3MTg2NzE2NgS2&b=2&j=NjY5MjEzNjgS1&mt=1&rt=0
LETTERS
Expansion and maintenance of human embryonic stem cell-derived endothelial cells by TGF[beta] inhibition is Id1 dependent pp161 - 166
Daylon James et al.
doi:10.1038/nbt.1605
James et al. describe a method for efficient differentiation of human embryonic stem cells into endothelial cells using TGF[beta] inhibition. Sustained expansion and maintenance of endothelial cells is shown to depend on expression of the vascular transcription factor Id1.
Abstract: http://links.ealert.nature.com/ctt?kn=107&m=34609148&r=MTc3MTg2NzE2NgS2&b=2&j=NjY5MjEzNjgS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=37&m=34609148&r=MTc3MTg2NzE2NgS2&b=2&j=NjY5MjEzNjgS1&mt=1&rt=0
Real-time imaging of hepatitis C virus infection using a fluorescent cell-based reporter system pp167 - 171
Christopher T Jones et al.
doi:10.1038/nbt.1604
Hepatitis C virus research is hampered by the inability to detect individual infected cells. Jones et al. achieve this by imaging the translocation of a fluorescent reporter protein after cleavage by a viral protease in living or fixed cells.
Abstract: http://links.ealert.nature.com/ctt?kn=103&m=34609148&r=MTc3MTg2NzE2NgS2&b=2&j=NjY5MjEzNjgS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=132&m=34609148&r=MTc3MTg2NzE2NgS2&b=2&j=NjY5MjEzNjgS1&mt=1&rt=0
Rational design of cationic lipids for siRNA delivery pp172 - 176
Sean C Semple et al.
doi:10.1038/nbt.1602
Efficient siRNA delivery remains a key challenge to realizing the full potential of RNAi-based therapeutics. Semple et al. accomplish unprecedented potency for liposome-mediated siRNA delivery by applying rational design to refine an empirically identified cationic lipid widely regarded as the benchmark for use in lipid nanoparticles.
Abstract: http://links.ealert.nature.com/ctt?kn=102&m=34609148&r=MTc3MTg2NzE2NgS2&b=2&j=NjY5MjEzNjgS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=141&m=34609148&r=MTc3MTg2NzE2NgS2&b=2&j=NjY5MjEzNjgS1&mt=1&rt=0
CORRIGENDA
Microdroplet-based PCR enrichment for large-scale targeted sequencing p178
Ryan Tewhey et al.
doi:10.1038/nbt0210-178a
http://links.ealert.nature.com/ctt?kn=139&m=34609148&r=MTc3MTg2NzE2NgS2&b=2&j=NjY5MjEzNjgS1&mt=1&rt=0
The valuation high ground p178
Jeffrey J Stewart and Ben Bonifant
doi:10.1038/nbt0210-178b
http://links.ealert.nature.com/ctt?kn=136&m=34609148&r=MTc3MTg2NzE2NgS2&b=2&j=NjY5MjEzNjgS1&mt=1&rt=0
Receptor-binding specificity of pandemic influenza A (H1N1) 2009 virus determined by carbohydrate microarray p178
Robert A Childs et al.
doi:10.1038/nbt0210-178c
http://links.ealert.nature.com/ctt?kn=147&m=34609148&r=MTc3MTg2NzE2NgS2&b=2&j=NjY5MjEzNjgS1&mt=1&rt=0
Small but not simple p178
Markus Elsner
doi:10.1038/nbt0210-178d
http://links.ealert.nature.com/ctt?kn=149&m=34609148&r=MTc3MTg2NzE2NgS2&b=2&j=NjY5MjEzNjgS1&mt=1&rt=0
ERRATA
A nuclear magnetic resonance technique for determining hybridoma cell concentration in hollow fiber bioreactors p178
Anthony Mancuso, Erik J Fernandez, Harvey W Blanch and Douglas S Clark
doi:10.1038/nbt0210-178e
http://links.ealert.nature.com/ctt?kn=156&m=34609148&r=MTc3MTg2NzE2NgS2&b=2&j=NjY5MjEzNjgS1&mt=1&rt=0
Can web 2.0 reboot clinical trials? p178
Malorye Allison
doi:10.1038/nbt0210-178f
http://links.ealert.nature.com/ctt?kn=159&m=34609148&r=MTc3MTg2NzE2NgS2&b=2&j=NjY5MjEzNjgS1&mt=1&rt=0
----------------------
CAREERS AND RECRUITMENT
----------------------
Fourth quarter lag in biotech hiring p179
Michael Francisco
doi:10.1038/nbt0210-179
http://links.ealert.nature.com/ctt?kn=152&m=34609148&r=MTc3MTg2NzE2NgS2&b=2&j=NjY5MjEzNjgS1&mt=1&rt=0
PEOPLE
People p180
doi:10.1038/nbt0210-180
http://links.ealert.nature.com/ctt?kn=100&m=34609148&r=MTc3MTg2NzE2NgS2&b=2&j=NjY5MjEzNjgS1&mt=1&rt=0
=========================== ADVERTISEMENT ===========================
FREE ARTICLES FROM SciBX
Pulmonary disease: Inhibiting HDAC7 in cystic fibrosis
Full text:http://links.ealert.nature.com/ctt?kn=32&m=34609148&r=MTc3MTg2NzE2NgS2&b=2&j=NjY5MjEzNjgS1&mt=1&rt=0
PDF: http://links.ealert.nature.com/ctt?kn=57&m=34609148&r=MTc3MTg2NzE2NgS2&b=2&j=NjY5MjEzNjgS1&mt=1&rt=0
Cancer: Targeting IDH1 in brain cancer
Full text: http://links.ealert.nature.com/ctt?kn=56&m=34609148&r=MTc3MTg2NzE2NgS2&b=2&j=NjY5MjEzNjgS1&mt=1&rt=0
PDF: http://links.ealert.nature.com/ctt?kn=61&m=34609148&r=MTc3MTg2NzE2NgS2&b=2&j=NjY5MjEzNjgS1&mt=1&rt=0
Musculoskeletal disease: New therapeutics for Spinal Muscular Atrophy
Full text: http://links.ealert.nature.com/ctt?kn=65&m=34609148&r=MTc3MTg2NzE2NgS2&b=2&j=NjY5MjEzNjgS1&mt=1&rt=0
PDF: http://links.ealert.nature.com/ctt?kn=63&m=34609148&r=MTc3MTg2NzE2NgS2&b=2&j=NjY5MjEzNjgS1&mt=1&rt=0
ACCESS MORE THAN 40 FREE ARTICLES from the SciBX Cover Story Archive
http://links.ealert.nature.com/ctt?kn=26&m=34609148&r=MTc3MTg2NzE2NgS2&b=2&j=NjY5MjEzNjgS1&mt=1&rt=0
=====================================================================
You have been sent this Table of Contents Alert because you have opted in to
receive it. You can change or discontinue your e-mail alerts at any time,
by modifying your preferences on your nature.com account at:
http://links.ealert.nature.com/ctt?kn=55&m=34609148&r=MTc3MTg2NzE2NgS2&b=2&j=NjY5MjEzNjgS1&mt=1&rt=0
(You will need to log in to be recognised as a nature.com registrant).
For further technical assistance, please contact our registration department:
registration@nature.com
For print subscription enquiries, please contact our subscription department:
subscriptions@nature.com
For other enquiries, please contact our customer feedback department:
feedback@nature.com
Nature Publishing Group | 75 Varick Street, 9th Floor | New York |
NY 10013-1917 | USA
Nature Publishing Group's worldwide offices:
London - Paris - Munich - New Delhi - Tokyo - Melbourne -
San Diego - San Francisco - Washington - New York - Boston
(c) Copyright 2010 Nature Publishing Group
=====================================================================
